Merck & Co., Inc. (NYSE:MRK) Rating Increased to Buy at Wall Street Zen

Merck & Co., Inc. (NYSE:MRK) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Saturday.

Several other research firms have also recently weighed in on MRK. Scotiabank increased their price target on shares of Merck & Co., Inc. from $105.00 to $120.00 and gave the company a “sector outperform” rating in a research note on Thursday, December 4th. Bank of America lifted their price target on shares of Merck & Co., Inc. from $105.00 to $120.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Wells Fargo & Company increased their price objective on Merck & Co., Inc. from $135.00 to $150.00 and gave the stock an “overweight” rating in a research report on Thursday, March 12th. Citigroup lifted their target price on Merck & Co., Inc. from $120.00 to $125.00 and gave the company a “neutral” rating in a research report on Friday, March 20th. Finally, Guggenheim upped their price target on Merck & Co., Inc. from $122.00 to $140.00 and gave the company a “buy” rating in a research note on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat, Merck & Co., Inc. presently has an average rating of “Moderate Buy” and a consensus price target of $127.13.

Merck & Co., Inc. Trading Up 0.7%

Shares of MRK stock opened at $119.77 on Friday. The company’s 50-day moving average price is $116.65 and its 200-day moving average price is $101.81. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89. The stock has a market cap of $296.13 billion, a price-to-earnings ratio of 16.45, a PEG ratio of 2.30 and a beta of 0.27. Merck & Co., Inc. has a twelve month low of $73.31 and a twelve month high of $125.14.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The firm had revenue of $16.40 billion during the quarter, compared to analyst estimates of $16.19 billion. During the same quarter in the prior year, the firm posted $1.72 earnings per share. Merck & Co., Inc.’s quarterly revenue was up 5.0% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. As a group, equities analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Insider Buying and Selling

In other news, EVP Richard R. Deluca sold 37,685 shares of the business’s stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $120.92, for a total transaction of $4,556,870.20. Following the completion of the transaction, the executive vice president directly owned 160,174 shares of the company’s stock, valued at approximately $19,368,240.08. The trade was a 19.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CMO Chirfi Guindo sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $118.41, for a total transaction of $1,184,100.00. Following the sale, the chief marketing officer owned 70,615 shares in the company, valued at $8,361,522.15. The trade was a 12.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 320,176 shares of company stock worth $38,281,735 over the last ninety days. Company insiders own 0.13% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Kingdom Financial Group LLC. acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at $25,000. Darwin Wealth Management LLC grew its stake in shares of Merck & Co., Inc. by 237.4% during the third quarter. Darwin Wealth Management LLC now owns 307 shares of the company’s stock worth $26,000 after purchasing an additional 216 shares in the last quarter. Abound Financial LLC acquired a new position in shares of Merck & Co., Inc. during the fourth quarter worth $26,000. Prosperity Bancshares Inc purchased a new position in Merck & Co., Inc. in the fourth quarter valued at $26,000. Finally, Kilter Group LLC purchased a new position in Merck & Co., Inc. in the second quarter valued at $27,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck announced a US$6.7B acquisition of Terns Pharmaceuticals to add TERN-701 (an investigational oral CML therapy) to its oncology/hematology pipeline—a clear move to build revenue and R&D options ahead of Keytruda’s planned 2028 exclusivity loss. Merck Targets Post Keytruda Future With US$6.7b Terns Acquisition
• Positive Sentiment: RBC reiterated an Outperform and kept a $142 price target after Merck’s Terns call, signaling sell‑side support for the strategy despite questions about the transaction premium. RBC Reiterates Merck (MRK) Outperform
• Positive Sentiment: Agilent won FDA approval for the PD‑L1 22C3 companion diagnostic in esophageal/GEJ carcinoma, which can help identify patients for Keytruda treatment—supportive for near‑term uptake in that indication. Agilent receives FDA approval for PD-L1 1HC 22C3 pharmDx
• Positive Sentiment: High-profile bullish commentary (e.g., Jim Cramer) and option/trade ideas targeting MRK indicate elevated investor interest and constructive conviction in Merck as a defensive large‑cap pharma. Jim Cramer on Merck & Co.
• Neutral Sentiment: Analyst model tweaks are minor: Erste marginally raised FY2026 EPS estimates (from $5.12 to $5.13), reflecting limited near‑term changes to consensus earnings expectations. MarketBeat analyst update
• Neutral Sentiment: Coverage pieces note Merck has outperformed recently (stock up ~50% over six months); some articles offer tactical trade ideas (options/covered calls) that reflect market momentum rather than fundamental shifts. Merck Stock Soars 50% in 6 Months
• Negative Sentiment: Keytruda’s planned 2028 loss of exclusivity remains the central long‑term risk—analysts and articles stress patent cliff exposure and some weak vaccine sales, which temper valuation upside. Zacks: Merck Stock Soars 50% in 6 Months
• Negative Sentiment: The proposed Terns transaction may face rival interest and is the subject of a shareholder‑lawyer investigation (Kahn Swick & Foti), introducing deal execution, regulatory and legal risk that could delay or change terms. MSN: Merck’s Terns acquisition may face rival interest BusinessWire: KSF Investigation

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.